Hurt Aeron, Komadina Naomi, Deng Yi-Mo, Kaye Matthew, Sullivan Sheena, Subbarao Kanta, Barr Ian
WHO Collaborating Centre for Reference and Research on Influenza, The Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.
Department of Microbiology and Immunology, The University of Melbourne, The Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.
Euro Surveill. 2017 Nov;22(47). doi: 10.2807/1560-7917.ES.2017.22.47.17-00731.
For over a decade virtually all A(H3N2) influenza viruses have been resistant to the adamantane class of antivirals. However, during the 2017 influenza season in Australia, 15/461 (3.3%) adamantane-sensitive A(H3N2) viruses encoding serine at residue 31 of the M2 protein were detected, more than the total number identified globally during the last 6 years. A return to wide circulation of adamantane-sensitive A(H3N2) viruses would revive the option of using these drugs for treatment and prophylaxis.
在过去十多年里，几乎所有的甲型（H3N2）流感病毒都对金刚烷类抗病毒药物耐药。然而，在2017年澳大利亚流感季期间，检测到15株（占461株的3.3%）M2蛋白第31位残基编码丝氨酸的对金刚烷敏感的甲型（H3N2）病毒，这一数量超过了过去6年全球范围内鉴定出的此类病毒总数。对金刚烷敏感的甲型（H3N2）病毒重新广泛传播将使使用这些药物进行治疗和预防成为可能。
